Previous studies have focused on whether pretreatment CRP/Alb ratio is a sensitive factor for predicting tumor prognosis and found consistent results: the elevated pretreatment CRP/Alb ratio was associated with a shorter OS in tumor patients [17–23]. Here, ALB is linked to neoplasm.